Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock. Bio-Path Stock Performance NASDAQ BPTH opened at $0.18 on Tuesday. The business’s fifty day simple moving average is $0.16 and its 200-day […]

Leave a Reply

Your email address will not be published.

Previous post UBS Group Issues Pessimistic Forecast for Cross Country Healthcare (NASDAQ:CCRN) Stock Price
Next post Onto Innovation FY2025 EPS Decreased by Cantor Fitzgerald